CytoDyn (CYDY) Tax Provisions (2018 - 2026)

CytoDyn's (CYDY) quarterly Tax Provisions came in at -$81.0 in Q2 2019, up 100.0% on a QoQ basis from -$2.8 million in Q4 2018.

Analysis

CytoDyn (CYDY) Tax Provisions (2018 - 2026) Analysis & Trends

CytoDyn (CYDY) has 2 years of Tax Provisions data on file, last reported at -$81.0 in Q2 2019.

Quarterly Tax Provisions changed N/A year-over-year to -$81.0 in Q2 2019, while the trailing twelve-month figure through Feb 2020 was -$81.0 (up 100.0% YoY) and the FY2019 annual result came in at -$2.8 million, changed N/A from the prior year.
Tax Provisions advanced to -$81.0 in Q2 2019, from -$2.8 million in the prior quarter.
In the past five years, Tax Provisions ranged from a high of -$81.0 in Q2 2019 to a low of -$2.8 million in Q4 2018.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	138.77 Bn	130.92 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	85.51 Bn	77.52 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	63.51 Bn	58.32 Bn	1.37 Bn	-59.00 Mn
4	Moderna	58.20 Bn	53.06 Bn	52.00 Mn	15.00 Mn
5	Revolution Medicines	44.04 Bn	44.04 Bn	-	-
6	BeOne Medicines	39.99 Bn	34.89 Bn	1.53 Bn	75.45 Mn
7	Alnylam Pharmaceuticals	35.45 Bn	32.14 Bn	992.69 Mn	13.31 Mn
8	Royalty Pharma	28.40 Bn	27.56 Bn	-	-
9	Insmed	27.44 Bn	26.28 Bn	358.27 Mn	1.90 Mn
10	CytoDyn	257.86 Mn	257.86 Mn	-	-8.97 Mn

Historic Data

Download Data